Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 22.58 AUD 1.71% Market Closed
Market Cap: 7.6B AUD
Have any thoughts about
Telix Pharmaceuticals Ltd?
Write Note

Intrinsic Value

The intrinsic value of one TLX stock under the Base Case scenario is 16.34 AUD. Compared to the current market price of 22.58 AUD, Telix Pharmaceuticals Ltd is Overvalued by 28%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TLX Intrinsic Value
16.34 AUD
Overvaluation 28%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Telix Pharmaceuticals Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for TLX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about TLX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Telix Pharmaceuticals Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Telix Pharmaceuticals Ltd

Provide an overview of the primary business activities
of Telix Pharmaceuticals Ltd.

What unique competitive advantages
does Telix Pharmaceuticals Ltd hold over its rivals?

What risks and challenges
does Telix Pharmaceuticals Ltd face in the near future?

Has there been any significant insider trading activity
in Telix Pharmaceuticals Ltd recently?

Summarize the latest earnings call
of Telix Pharmaceuticals Ltd.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Telix Pharmaceuticals Ltd.

Provide P/S
for Telix Pharmaceuticals Ltd.

Provide P/E
for Telix Pharmaceuticals Ltd.

Provide P/OCF
for Telix Pharmaceuticals Ltd.

Provide P/FCFE
for Telix Pharmaceuticals Ltd.

Provide P/B
for Telix Pharmaceuticals Ltd.

Provide EV/S
for Telix Pharmaceuticals Ltd.

Provide EV/GP
for Telix Pharmaceuticals Ltd.

Provide EV/EBITDA
for Telix Pharmaceuticals Ltd.

Provide EV/EBIT
for Telix Pharmaceuticals Ltd.

Provide EV/OCF
for Telix Pharmaceuticals Ltd.

Provide EV/FCFF
for Telix Pharmaceuticals Ltd.

Provide EV/IC
for Telix Pharmaceuticals Ltd.

Show me price targets
for Telix Pharmaceuticals Ltd made by professional analysts.

What are the Revenue projections
for Telix Pharmaceuticals Ltd?

How accurate were the past Revenue estimates
for Telix Pharmaceuticals Ltd?

What are the Net Income projections
for Telix Pharmaceuticals Ltd?

How accurate were the past Net Income estimates
for Telix Pharmaceuticals Ltd?

What are the EPS projections
for Telix Pharmaceuticals Ltd?

How accurate were the past EPS estimates
for Telix Pharmaceuticals Ltd?

What are the EBIT projections
for Telix Pharmaceuticals Ltd?

How accurate were the past EBIT estimates
for Telix Pharmaceuticals Ltd?

Compare the revenue forecasts
for Telix Pharmaceuticals Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Telix Pharmaceuticals Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Telix Pharmaceuticals Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Telix Pharmaceuticals Ltd compared to its peers.

Compare the P/E ratios
of Telix Pharmaceuticals Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Telix Pharmaceuticals Ltd with its peers.

Analyze the financial leverage
of Telix Pharmaceuticals Ltd compared to its main competitors.

Show all profitability ratios
for Telix Pharmaceuticals Ltd.

Provide ROE
for Telix Pharmaceuticals Ltd.

Provide ROA
for Telix Pharmaceuticals Ltd.

Provide ROIC
for Telix Pharmaceuticals Ltd.

Provide ROCE
for Telix Pharmaceuticals Ltd.

Provide Gross Margin
for Telix Pharmaceuticals Ltd.

Provide Operating Margin
for Telix Pharmaceuticals Ltd.

Provide Net Margin
for Telix Pharmaceuticals Ltd.

Provide FCF Margin
for Telix Pharmaceuticals Ltd.

Show all solvency ratios
for Telix Pharmaceuticals Ltd.

Provide D/E Ratio
for Telix Pharmaceuticals Ltd.

Provide D/A Ratio
for Telix Pharmaceuticals Ltd.

Provide Interest Coverage Ratio
for Telix Pharmaceuticals Ltd.

Provide Altman Z-Score Ratio
for Telix Pharmaceuticals Ltd.

Provide Quick Ratio
for Telix Pharmaceuticals Ltd.

Provide Current Ratio
for Telix Pharmaceuticals Ltd.

Provide Cash Ratio
for Telix Pharmaceuticals Ltd.

What is the historical Revenue growth
over the last 5 years for Telix Pharmaceuticals Ltd?

What is the historical Net Income growth
over the last 5 years for Telix Pharmaceuticals Ltd?

What is the current Free Cash Flow
of Telix Pharmaceuticals Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Telix Pharmaceuticals Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Telix Pharmaceuticals Ltd

Current Assets 255.3m
Cash & Short-Term Investments 118.8m
Receivables 97.3m
Other Current Assets 39.2m
Non-Current Assets 490.7m
Long-Term Investments 10.5m
PP&E 38.3m
Intangibles 399.5m
Other Non-Current Assets 42.5m
Current Liabilities 258.4m
Accounts Payable 22.3m
Accrued Liabilities 67.3m
Other Current Liabilities 168.8m
Non-Current Liabilities 83.6m
Long-Term Debt 18.4m
Other Non-Current Liabilities 65.2m
Efficiency

Earnings Waterfall
Telix Pharmaceuticals Ltd

Revenue
645.7m AUD
Cost of Revenue
-246.6m AUD
Gross Profit
399m AUD
Operating Expenses
-325.4m AUD
Operating Income
73.7m AUD
Other Expenses
-24.5m AUD
Net Income
49.2m AUD

Free Cash Flow Analysis
Telix Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

The company maintains its planned R&D expenditures around $100-$105 million, with additional costs for preparing commercial manufacturing once two new diagnostic assets are approved. Current trials show good tolerance in patients, with results expected early next year. While hoping for a priority review of their breakthrough designation, the official PDUFA goal date is yet to be finalized. The contingent consideration regarding a technological acquisition reflects a percentage of 12-month sales, already accounted for in the balance sheet, indicating clear expectations from Illuccix sales, capped upon certain preconditions.

What is Earnings Call?
Fundamental Scores

TLX Profitability Score
Profitability Due Diligence

Telix Pharmaceuticals Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
45/100
Profitability
Score

Telix Pharmaceuticals Ltd's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

TLX Solvency Score
Solvency Due Diligence

Telix Pharmaceuticals Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Negative Net Debt
Low D/E
Long-Term Solvency
64/100
Solvency
Score

Telix Pharmaceuticals Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TLX Price Targets Summary
Telix Pharmaceuticals Ltd

Wall Street analysts forecast TLX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TLX is 26.46 AUD with a low forecast of 21.82 AUD and a high forecast of 35.07 AUD.

Lowest
Price Target
21.82 AUD
3% Downside
Average
Price Target
26.46 AUD
17% Upside
Highest
Price Target
35.07 AUD
55% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for TLX?

Click here to dive deeper.

Dividends

Telix Pharmaceuticals Ltd
does not pay dividends
Shareholder Yield

Current shareholder yield for TLX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TLX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

TLX News

Other Videos

Profile

Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd

Country

Australia

Industry

Biotechnology

Market Cap

7.5B AUD

Dividend Yield

0%

Description

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria and currently employs 158 full-time employees. The company went IPO on 2017-11-15. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The firm's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.

Contact

VICTORIA
Melbourne
U 401 55 Flemington Rd
www.telixpharma.com

IPO

2017-11-15

Employees

158

Officers

Co-Founder, MD, Group CEO & Executive Director
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA
Group Chief Financial Officer
Mr. Darren Smith B.Bus., FCPA, M.B.A.
Chief Medical Advisor
Dr. Andreas Kluge M.D., Ph.D.
Group Chief Medical Officer
Dr. David N. Cade M.B.A., M.D., MBBS
Chief Executive Officer of Telix Therapeutics
Mr. Richard Valeix M.B.A.
Group Chief Operating Officer
Mr. Darren Patti
Show More
Chief Scientist
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab)
Chief Information Officer
Mr. Craig Ulrick
Senior Vice President of Corporate Communications & Investor Relations
Ms. Kyahn Williamson B.A.
Group General Counsel
Ms. Lena Moran-Adams L.L.B.
Show Less

See Also

Discover More
What is the Intrinsic Value of one TLX stock?

The intrinsic value of one TLX stock under the Base Case scenario is 16.34 AUD.

Is TLX stock undervalued or overvalued?

Compared to the current market price of 22.58 AUD, Telix Pharmaceuticals Ltd is Overvalued by 28%.

Back to Top